Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
I-Mab(I-Mab) is a biopharmaceutical company. It develops transformational medicines for therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. The company collaborates with biotechnology companies, CROs, and CMOs to advance the clinical development of its pipeline assets and out-licensing opportunities. It operates in China, Hong Kong and the US. I-Mab is headquartered in Shanghai, China.
I-Mab premium industry data and analytics
Products and Services
Products |
---|
TJ202 (Felzartamab): Multiple Myeloma |
TJ101 (Eftansomatropin): Pediatric Growth Hormone Deficiency |
TJ271 (Enoblituzumab): Non-Small Cell Lung Cancer |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In February, the company signed agreements to divest its assets and business operations in China. |
2022 | Others | In August, the company announced to concentrate its drug development efforts on five key candidates. |
2022 | Contracts/Agreements | In June, the company entered into a strategic collaboration with Ferring Pharmaceuticals to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions. |
Competitor Comparison
Key Parameters | I-Mab | Akeso Inc | CStone Pharmaceuticals Co Ltd | JW Cayman Therapeutics Co Ltd | CARsgen Therapeutics Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | China | China | China | China |
City | Rockville | Zhongshan | Shanghai | Shanghai | Shanghai |
State/Province | Maryland | Guangdong | Shanghai | Shanghai | Shanghai |
No. of Employees | 318 | 2,778 | 230 | 398 | 516 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Jingwu Zhang Zang | Chairman | Executive Board | 2021 | 67 |
Richard Yeh | Chief Financial Officer - Interim; Chief Operating Officer; Director | Executive Board | 2022 | 54 |
Andrew Zhu | Chief Executive Officer - Acting; President; Director | Executive Board | 2021 | 62 |
Raj Kannan | Chief Executive Officer | Senior Management | 2023 | - |
Richard Cheng Li | Chief Legal Officer | Senior Management | 2021 | 38 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer